Advances on the role of pegaspargase in the treatment of childhood leukemia / 中国当代儿科杂志
Chinese Journal of Contemporary Pediatrics
;
(12): 155-160, 2014.
Article
in Chinese
| WPRIM
| ID: wpr-269518
ABSTRACT
The chemotherapy agent L-asparaginase (L-asp) has been an important part of acute lymphoblastic leukemia therapy for over 30 years. It is evident that L-asp has a long-term curative effect. However, L-asp is associated with high incidence of adverse reactions. This has prompted the development of pegylated asparaginase (PEG-asp), which has undergone extensive testing. Apparently, PEG-asp has a prolonged half-life with a better tolerance profile while retaining the antileukemic effect. In this review, we attempt to outline the history of clinical application of L-asp, the pharmacological and clinical potential of various preparations of L-asp, the development of PEG-asp, and the clinical application and adverse events of PEG-asp. The literatures reviewed in this article is collected through online search of the major databases both in English and Chinese.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Pancreatitis
/
Pharmacology
/
Polyethylene Glycols
/
Asparaginase
/
Blood Coagulation Disorders
/
Pharmacokinetics
/
Therapeutic Uses
/
Drug Therapy
/
Precursor Cell Lymphoblastic Leukemia-Lymphoma
/
Antineoplastic Agents
Limits:
Humans
Language:
Chinese
Journal:
Chinese Journal of Contemporary Pediatrics
Year:
2014
Type:
Article
Similar
MEDLINE
...
LILACS
LIS